Dolutegravir safe and highly effective in older children
Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed
Tenofovir alafenamide PrEP protects monkeys from infection, but rectal and vaginal levels in humans may be too low
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity
PopART trial shows feasibility of reaching 90-90-90 targets for testing and treatment coverage in Zambia and South Africa
Botswana close to reaching the 90-90-90 testing and treatment targets
Cotrimoxazole prophylaxis provides no benefit for HIV-exposed uninfected children
Partner notification feasible and effective in African settings
Very high levels of chemsex and ‘slamsex’ seen in HIV-positive men attending English/Welsh HIV clinics
Option B+ cuts mother-to-child HIV transmission dramatically in Malawi
Starting HIV treatment at first clinic visit improves outcomes in African study
Major disparities persist in lifetime risk of HIV diagnosis in the US
During pregnancy, offering HIV testing at home doubles the proportion of male partners who test
People with HIV considerably overestimate their chance of infecting someone
Bone density recovers quickly after stopping PrEP
Dose-finding trials of antibody-based drugs for HIV prevention will start soon
Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy
Early antiretroviral therapy has no impact on marker of early cardiovascular disease
